HSBC’s $38,000-a-Child Hong Kong Perk Is in the Crosshairs as Cost Cuts Bite

April 27, 2026
HSBC’s $38,000-a-Child Hong Kong Perk Is in the Crosshairs as Cost Cuts Bite

HONG KONG, April 27, 2026, 19:07 HKT

HSBC Holdings Plc is taking another look at a decades-old perk for its Hong Kong bankers—one that covers private school tuition—Bloomberg News reported Monday, citing people with knowledge of the situation. Chief Executive Georges Elhedery is behind the broader cost-cutting drive that’s also targeting benefit standardisation. Among the options on the table: ending the subsidy for those joining the bank in future, or making tweaks to overall pay packages, according to the report.

The timing’s key here. HSBC will post its first-quarter numbers at noon Hong Kong time on May 5, letting investors see if the bank is managing to control costs and still defend returns in its biggest profit market.

This perk hardly shows up alongside the likes of a loan book or trading desk on the balance sheet. Still, it serves as a clear signal of just how committed HSBC is to its expense targets. The bank has told investors it’s aiming for roughly 1% growth this year in “target basis” operating expenses—a figure that excludes significant one-off charges. HSBC

Reports say that mid-level and senior staff in Hong Kong are eligible for a subsidy that covers 95% of annual school fees—capped at HK$220,000 per primary school child and HK$300,000 for those in secondary. The benefit, available to hundreds of employees, ends up costing the company tens of millions of dollars each year, according to the reports.

Elhedery, appointed in 2024, has slashed management ranks and reorganized the group to focus sharply on eastern and western markets. Speaking with Bloomberg Television—remarks later picked up by the Guardian—he described himself as “ruthless about killing complexity” in his push to streamline HSBC and boost agility. The Guardian

The push is now hitting a nerve when it comes to pay. In Hong Kong, international school fees chew up a big chunk of family budgets. Any tweak here may look like a pay cut to staff caught by the change—even if HSBC calls it benefit harmonisation.

HSBC faces a trickier situation in Hong Kong, where it stands as one of only three banks authorized to issue banknotes—joining Standard Chartered Bank Hong Kong and Bank of China Hong Kong. Its brand is tightly woven into the city’s financial fabric, commanding influence that goes beyond what most overseas banks can claim.

HSBC’s review comes on the heels of its complete acquisition of Hang Seng Bank. The bank confirmed the privatisation took effect Jan. 26, with Hang Seng shares coming off the Hong Kong Stock Exchange the following day. That move leaves Hang Seng as a fully owned HSBC subsidiary.

Back in February, Elhedery told investors HSBC was turning into “a simple, more agile, focused bank,” after bumping up its return on tangible equity goal to at least 17% for 2026 through 2028. That’s profit measured against shareholder capital, stripped of intangible assets. For 2025, HSBC posted a pre-tax profit of $29.9 billion, with operating expenses coming in at $36.4 billion. HSBC

Saving a bit of money on paper could easily backfire, turning into a morale issue. Perks like school-fee assistance, discounted mortgages, and club memberships have long been HSBC’s way of luring bankers in Asia, where Wall Street rivals typically offer fatter cash paychecks.

HSBC shares barely budged Monday. On HSBC’s investor site—where a delayed Refinitiv feed is used—the Hong Kong stock ticked up just HK$0.20 to HK$140.20, while the London line advanced 9.20 pence to 1,330.16 pence at 10:53 GMT.

The tougher figure lands next week. Should HSBC’s first-quarter costs come in high, a school-fee review could appear as just one piece of a wider cost clampdown. If expenses remain steady, it still suggests Elhedery is hunting for efficiencies where earlier management didn’t tread.

Stock Market Today

  • AstraZeneca Outlook Remains Steady as Daiichi Review Proceeds
    April 27, 2026, 7:37 AM EDT. AstraZeneca's outlook stays steady amid ongoing review of its partnership with Daiichi Sankyo. The review aims to assess the strategic fit and operational performance of the collaboration, which focuses on developing and commercializing cancer therapies. Market watchers note that AstraZeneca's share performance reflects cautious optimism as the review progresses. No immediate changes to forecasts or guidance were announced. The review could influence AstraZeneca's future investment and R&D priorities. Investors are advised to monitor updates closely given the potential impact on AstraZeneca's pipeline and financial outlook. AstraZeneca continues to focus on enhancing its oncology portfolio, a key driver for growth.